New pharmacological options in the treatment of Alzheimer's disease
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Ceska a slovenska neurologie a neurochirurgie |
| Citation | |
| web | https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2022-6-10/new-pharmacological-options-in-the-treatment-of-alzheimer-s-disease-133181 |
| Doi | http://dx.doi.org/10.48095/cccsnn2022462 |
| Keywords | Alzheimer?s disease; phase three testing of new drugs; ß -amyloid; tau protein; neuroinflammatory theory; ric symptoms; neuroprotection |
| Description | A new era of innovative treatment options for Alzheimer's disease is emerging. New goals of treatment are being developed with various monoclonal antibodies targeting potentially pathological molecules involved in the pathogenesis of Alzheimer's disease. The aim of this review is to acquaint the reader with new potential drugs, while most of those mentioned in this review are in the third phase of clinical trials. |